-
Something wrong with this record ?
The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes
M. Stiborová, V. Černá, M. Moserová, I. Mrízová, VM. Arlt, E. Frei,
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
25547492
DOI
10.3390/ijms16010284
Knihovny.cz E-resources
- MeSH
- Cytochrome P-450 CYP1A1 deficiency genetics metabolism MeSH
- Ellipticines pharmacology MeSH
- Hepatocytes drug effects metabolism MeSH
- Rats MeSH
- Mice MeSH
- DNA Damage * MeSH
- Antineoplastic Agents pharmacology MeSH
- Uncoupling Agents pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031540
- 003
- CZ-PrNML
- 005
- 20171215201515.0
- 007
- ta
- 008
- 151005s2015 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms16010284 $2 doi
- 035 __
- $a (PubMed)25547492
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Stiborová, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. stiborov@natur.cuni.cz.
- 245 14
- $a The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes / $c M. Stiborová, V. Černá, M. Moserová, I. Mrízová, VM. Arlt, E. Frei,
- 520 9_
- $a Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b5 alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b5, activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b5, and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a cytochrom P-450 CYP1A1 $x nedostatek $x genetika $x metabolismus $7 D019363
- 650 12
- $a poškození DNA $7 D004249
- 650 _2
- $a elipticiny $x farmakologie $7 D004611
- 650 _2
- $a hepatocyty $x účinky léků $x metabolismus $7 D022781
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a rozpřahující látky $x farmakologie $7 D014475
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Černá, Věra $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. vera.cerna@natur.cuni.cz.
- 700 1_
- $a Moserová, Michaela $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. michaela.moserova@natur.cuni.cz.
- 700 1_
- $a Mrízová, Iveta $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030, CZ-12843 Prague 2, Czech Republic. iveta.vranova@natur.cuni.cz.
- 700 1_
- $a Arlt, Volker M. $u Analytical and Environmental Sciences Division, MRC-PHE Centre for Environmental & Health, King's College London, 150 Stamford Street, London SE1 9NH, UK. volker.arlt@kcl.ac.uk. $7 xx0074763 $4
- 700 1_
- $a Frei, Eva $u Division of Preventive Oncology, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. eva.frei@t-online.de.
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 16, č. 1 (2015), s. 284-306
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25547492 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151013104113 $b ABA008
- 999 __
- $a ok $b bmc $g 1092416 $s 914666
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 16 $c 1 $d 284-306 $e 20141225 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- LZP __
- $a Pubmed-20151005